Testop 100mg/ml 10x1ml Ampullen by Raw Pharma

Usage

1. Confirm your SARM and its approximate half-life before scheduling Testosterone Propionate injections — align injection frequency so both compounds are active simultaneously throughout the cycle.
2. Snap the ampoule neck cleanly at the score ring using an ampoule opener; draw the full 1 ml or your required volume into a 23–25 gauge needle syringe, then switch to a fresh injection needle.
3. Rotate injection sites — glutes, vastus lateralis, and deltoids in sequence — to distribute oil-depot discomfort across multiple sites when combined with other injectables in a SARM support protocol.
4. Administer intramuscularly at your scheduled interval (every other day or three times weekly); maintain consistent spacing to keep plasma testosterone stable across the SARM cycle duration.
5. Monitor oestradiol levels at weeks 3–4 using a sensitive ELISA assay; because propionate contributes aromatisable substrate even at low doses, aromatase inhibitor support may be required at the low end of dosing for sensitive individuals.
6. On the final Testosterone Propionate injection, log the date and count forward 5–7 days before starting PCT — this ensures both propionate and any co-administered SARMs have cleared to sub-suppressive levels before SERM administration begins.

Warnings

Frequently asked questions

Can Testosterone Propionate be used as a base compound during a SARM cycle?

Yes — Testosterone Propionate is one of the most appropriate androgenic base compounds for SARM cycles. SARMs suppress natural testosterone production to varying degrees while providing only tissue-selective androgenic signalling; adding Testosterone Propionate at 100–150 mg per week restores full systemic androgenic coverage, preventing libido suppression, mood disruption, and connective-tissue degradation that occur in testosterone-deficient SARM-only cycles.

Which SARMs pair most effectively with Testosterone Propionate 100 mg/ml?

LGD-4033, RAD-140, and Ostarine are the most commonly documented SARM partners for Testosterone Propionate. LGD-4033 targets lean mass accrual while propionate maintains androgenic tone; RAD-140 provides high anabolic selectivity and pairs with propionate to cover non-skeletal androgenic tissues; Ostarine suits milder recomposition cycles where a low 100 mg/week propionate dose preserves baseline androgenic function without interfering with Ostarine's mild tissue selectivity.

Why does the propionate ester make post-cycle planning easier in a SARM stack compared to longer-ester testosterone?

Because propionate and most SARMs share comparable elimination timelines — propionate clears in roughly 4–7 days after the last injection, while RAD-140 and LGD-4033 clear within approximately 5–10 days at standard doses. This alignment allows a single SERM-based PCT start date to cover both compounds simultaneously, avoiding the staggered recovery window required when testosterone enanthate (7-day half-life) is combined with shorter-acting SARMs.

What is the advantage of single-dose 1 ml ampoules versus a multi-dose vial for a SARM combination cycle?

Each Testop ampoule is factory-sealed by glass fusion and used in its entirety for one injection, eliminating the repeated rubber-stopper punctures and cumulative contamination risk associated with multi-dose vials. For SARM cycles that already involve multiple oral or injectable administrations, the single-dose format simplifies sterility management and removes the need to track partial vial integrity across a 6–10 week run.

Is 100 mg/ml the right concentration for precise low-dose testosterone support during a SARM protocol?

At 100 mg/ml, Testop is the lowest concentration in its product group and is particularly well suited to conservative SARM-support dosing. A 50 mg dose requires only a 0.5 ml draw, and a 33 mg dose requires 0.33 ml — both measurable accurately in a standard 1 ml syringe without the rounding errors that higher-concentration preparations introduce at sub-100 mg injection volumes. This precision matters when the goal is to hold testosterone in the mid-physiological range rather than pushing it supraphysiologically. (2) angle_used

Manufacturer

Sterility and aseptic production quality are the two non-negotiable pillars of Raw Pharma's injectable manufacturing framework — and Testop reflects both without compromise. Each batch of Testosterone Propionate 100 mg/ml is processed under positive-pressure cleanroom conditions: the oil solution passes through validated 0.22 µm membrane filtration before filling, with environmental monitoring logs maintained for every production session. Glass ampoule sealing is completed by automated heat-fusion equipment, producing a hermetic closure that eliminates post-fill contamination pathways entirely — a critical distinction from rubber-stopper vial formats where repeated puncture introduces particulate and microbiological risk. Before release, every Testop lot undergoes LAL endotoxin testing against parenteral-safety thresholds defined in the European Pharmacopoeia, and HPLC potency analysis confirms the 100 mg/ml active-ingredient specification within the declared acceptance range. A Certificate of Analysis documenting both results is assigned to the batch number and remains traceable through the distribution chain to the end customer.